A targeted analytical method was established to determine tralopyril (4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile) in water. This compound has been recently introduced as a biocide in ship antifouling paints, becoming a potential new environmental contaminant. The method presented here allows for the first time the direct determination of tralopyril in environmental samples without the need of a pre-concentration step. The injected sample is separated by a 30 min HPLC-gradient on a reversed phase column and the compound identified and quantified by negative ion LC-MS/MS. Tralopyril solutions in DMSO, seawater, river Glatt water and E3 medium (used for zebrafish experiments) were analysed to demonstrate the applicability of the method. The method provides good retention time reproducibility and a quantitation limit (LOQ) of 0.025 μg L(-1) for DMSO, seawater and E3 exposure medium and 0.05 μg L(-1) for river Glatt water. Calculated tralopyril half-lives were 6.1 h for seawater, 8.1 h for river Glatt water and 7.4 h for E3 medium at 18 °C.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.chemosphere.2015.11.098 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effect of LRRK2 loss-of-function variants in humans.
Nat Med
June 2020
Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Human genetic variants predicted to cause loss-of-function of protein-coding genes (pLoF variants) provide natural in vivo models of human gene inactivation and can be valuable indicators of gene function and the potential toxicity of therapeutic inhibitors targeting these genes. Gain-of-kinase-function variants in LRRK2 are known to significantly increase the risk of Parkinson's disease, suggesting that inhibition of LRRK2 kinase activity is a promising therapeutic strategy. While preclinical studies in model organisms have raised some on-target toxicity concerns, the biological consequences of LRRK2 inhibition have not been well characterized in humans.
View Article and Find Full Text PDFThe mutational constraint spectrum quantified from variation in 141,456 humans.
Nature
May 2020
Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Genetic variants that inactivate protein-coding genes are a powerful source of information about the phenotypic consequences of gene disruption: genes that are crucial for the function of an organism will be depleted of such variants in natural populations, whereas non-essential genes will tolerate their accumulation. However, predicted loss-of-function variants are enriched for annotation errors, and tend to be found at extremely low frequencies, so their analysis requires careful variant annotation and very large sample sizes. Here we describe the aggregation of 125,748 exomes and 15,708 genomes from human sequencing studies into the Genome Aggregation Database (gnomAD).
View Article and Find Full Text PDFEvaluating drug targets through human loss-of-function genetic variation.
Nature
May 2020
Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Naturally occurring human genetic variants that are predicted to inactivate protein-coding genes provide an in vivo model of human gene inactivation that complements knockout studies in cells and model organisms. Here we report three key findings regarding the assessment of candidate drug targets using human loss-of-function variants. First, even essential genes, in which loss-of-function variants are not tolerated, can be highly successful as targets of inhibitory drugs.
View Article and Find Full Text PDFLandscape of multi-nucleotide variants in 125,748 human exomes and 15,708 genomes.
Nat Commun
May 2020
Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
Multi-nucleotide variants (MNVs), defined as two or more nearby variants existing on the same haplotype in an individual, are a clinically and biologically important class of genetic variation. However, existing tools typically do not accurately classify MNVs, and understanding of their mutational origins remains limited. Here, we systematically survey MNVs in 125,748 whole exomes and 15,708 whole genomes from the Genome Aggregation Database (gnomAD).
View Article and Find Full Text PDFA cross-species translational pharmacokinetic-pharmacodynamic evaluation of core body temperature reduction by the TRPM8 blocker PF-05105679.
Eur J Pharm Sci
November 2017
Certara QSP, Canterbury Innovation Centre, Canterbury CT2 7FG, UK; Systems Pharmacology Cluster, Division of Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands.
Article Synopsis
- PF-05105679 is a moderate TRPM8 blocker being studied for its potential to treat cold pain sensitivity, as TRPM8 is linked to cold sensation and core body temperature regulation.
- Its effects were tested in animals, revealing that it can lower body temperature, with the degree of temperature drop depending on the body weight of the species.
- In human trials, PF-05105679 successfully alleviated cold pain without affecting core body temperature, supporting its therapeutic potential without unwanted side effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!